Cytodyn
Biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses.
Launch date
Employees
Market cap
AUD281m
Enterprise valuation
AUD323m (Public information from Sep 2024)
Share price
$0.16 CYDY
Lake Oswego Oregon (HQ)
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | <1m | - | - |
EBITDA | - | - | (73.4m) | (93.0m) | (80.2m) | (64.1m) | (30.5m) |
% EBITDA margin | - | - | - | - | (30169 %) | - | - |
Profit | - | - | (124m) | (155m) | (211m) | (79.8m) | (49.8m) |
% profit margin | - | - | - | - | (79256 %) | - | - |
EV / revenue | - | - | - | - | 989.5x | - | - |
EV / EBITDA | - | - | -20.8x | -13.1x | -3.3x | -4.3x | -6.0x |
R&D budget | - | - | 52.6m | 58.4m | 27.0m | 2.6m | 7.2m |
R&D % of revenue | - | - | - | - | 10167 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $3.0m | Post IPO Equity | |
N/A | N/A | Growth Equity VC | |
N/A | $5.9m | Post IPO Equity | |
N/A | $1.2m | Convertible | |
N/A | $3.2m | Post IPO Equity | |
N/A | $3.3m | Post IPO Debt | |
N/A | $2.7m | Post IPO Equity | |
N/A | $5.9m | Post IPO Equity | |
N/A | $4.3m | Post IPO Equity | |
N/A | $15.0m | Post IPO Debt | |
Total Funding | AUD5.4m |
Related Content
Recent News about Cytodyn
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.